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The process of consent
 The process should be tailored to the type of study and

circumstances of the populations being recruited:

 How much time will the individual have to consider

participation?
 Where will the consent process occur? The setting should be
private.
 Individuals involved in the consent process should have a
good understanding of the study and be able to answer
questions.


For treatment studies, we would expect there will be an overlap of
clinical and research questions.

 The overall consent process (timing, setting and presentation

of the study) should occur under circumstances that avoid
coercion or undue influence.

Who can obtain consent?
 This should be described in your IRB application.
 The IRB can require that certain individuals be

involved in the consent process.

 Example: The IRB could determine that based on the

risk and complexity of the study only the PI may obtain
consent.

 If the consent process is delegated by the PI to another

individual they must be
 fully trained

 aware of all aspects of the study and;
 the PI must still be available to answer questions

Residents obtaining consent
 There are Institutional requirements for Human






Subject Research Training
Satisfaction of this requirement is tracked in the
myIRB application.
IRB must be aware of and approve all individuals
“engaged” in the research to ensure qualifications and
define IRB oversight.
Adding someone to the myIRB application-DEMO!!
The PI is responsible for ensuring that these
individuals have a good understanding of the study
and can answer questions.

The Consent Document
 The consent document is the only written record we

have that says exactly what it is that you will tell the
subject.
 It must contain all information that a reasonable
person needs to know to decide whether or not to
participate in the study.
 Should be presented in a way that is understandable.
 It must contain information that addresses specific
regulatory requirements.

Signing the Consent Document
 IRB policy:
 Participant and person obtaining consent must sign and
date the consent document
 The participant (LAR, if applicable) must be provided
with a signed copy of the consent document.

Signing the Consent Document
 Until the participant signs the consent document do not

make assumptions based on earlier conversations

 The participant could be in full agreement and the next

day/hour/minute change their mind.
 Once the participant signs, it will be the responsibility of the
participant to let you know if they changed their mind.

 Person obtaining consent
 Not advisable to sign prior to the participant…why?




See prior bullet point
A “meeting of the minds”, “a mutual agreement”
Can create questions about the validity of the consent process.

 Investigator acknowledgement
 Not an IRB requirement

Signing the Consent Document
 The participant:
 “Your signature indicates that this research study has

been explained to you, that your questions have been
answered, and that you agree to take part in this study.”
 Person obtaining consent:
 “The information in this document has been discussed
with the participant or, where appropriate, with the
participant’s legally authorized representative. The
participant has indicated that he or she understands the
risks, benefits, and procedures involved with
participation in this research study.”

Timing of Consent
 The amount of time required by a subject to make a

decision will depend on the nature of the study, the
degree of risk, potential benefits, alternatives, and
desire to consult with family members or others.
 If a prolonged period of time elapses from the date of
consent to the date of entry into the study even if there
have been no changes in the study design or no new
significant findings affecting the study it might be
prudent to review the information contained in the
consent form with the subject prior to initiating any
research procedures with the subject.


OHRP FAQs on consent

Decisionally impaired
individuals
 Enrolling individuals that are decisionally impaired or that could

become decisionally impaired over time requires IRB approval.
 Considered a vulnerable population
 IRB will want to know:
 Why is it ethically appropriate to include this population?
 In the alternative, consider if it is appropriate to exclude the
population.
 How will you assess competency?
 Will you obtain assent from the participant?
 How will you consent the LAR?
 How will you ensure the LAR understands their role?

Use of the LAR
 Who can sign?
 If the participant has a legal guardian or attorney-in-fact

this individual must sign as the LAR.

 If there is no legal guardian or attorney-in-fact the individuals

listed below may sign in order of priority.







(1) Spouse unless the participant has no spouse, or is separated, or
the spouse is physically or mentally incapable of giving consent, or
the spouse's whereabouts is unknown or the spouse is overseas;
(2) Adult child;
(3) Parent;
(4) Brother or sister;
(5) Relative by blood or marriage.

Use of the LAR
 How to use the priority list
 Recognize that this process is different than in the
clinical setting
 There is no “reasonably available” exception when going
down the priority list.
 For example, if the participant does not have a spouse
but has an adult child, that is the person that can
provide consent. You cannot go to the parent if they are
more conveniently available.

Use of LAR in minimal risk studies
 Possible policy change forthcoming
 For minimal risk studies where there is no legally

appointed representative will allow other individuals
listed on the priority list to give consent even if not
first on the list.

Non-English Speakers
 Enrolling individuals that do not speak English

requires prior IRB approval.
 Whenever possible, the consent document should be
in a language understandable to the subject, and
include all the elements necessary for legally effective
informed consent. Subjects who do not speak English
should be presented with a consent document written
in a language understandable to them. Memo from OHRP

Short Form
 A “short form” includes an oral presentation of informed consent in

conjunction with a short form document (stating that the elements of
consent have been presented orally) and a written summary of what is
presented orally. A witness to the oral presentation is required, and the
subject must be given copies of the short form document and the
summary.
 Oral presentation and short form should be in language
understandable to the subject
 The English version of the consent may serve as the summary
 The witness should be fluent in both English and the language of
the subject
 Short form signed by participant, the summary signed by person
obtaining consent, the short form and summary signed by the
witness (the translator may be the witness)

Allowing use of the short form
 When would the IRB allow use of the short form in lieu of a

fully translated consent?
 The issue: Depending on the type of study the
participant may need a reference document (the
consent) or ongoing translational support to stay fully
informed once they go home.
 How complex is the study, what are the risks, what is the
ongoing involvement of the participant?

Other unique challenges
 Physically unable to sign
 Visual impairments
 Unable to read or write
 “Making their Mark”
 We have guidance!!

Physically unable to sign
 The individual must be competent.
 The individual must be able to indicate their approval

or disapproval

 Verbal, raise hand, nod
 “making their mark” is considered a valid signature

 Person obtaining consent should document the

method used to communicate approval on the consent
 Impartial witness present during consent process
 Below signature block have witness sign and indicate

they witnessed the consent process and the individual
agreed to participant by <insert method>.

Visual impairments/Cannot read or write
 The individual must be competent.
 The individual is able to indicate their approval or

disapproval.
 There must be continuing support to relay information in
the consent document such as: what is involved, risks,
contact information for PI and WU IRB.
 Procedure:
 document method of agreement, if not signing consent or

“making mark”
 impartial witness present during consent process
 written attestation to consent process by witness

Take home points
 The consent process is a critical element of good

human subjects research and a critical part of the IRB
review process.
 The consent process will be driven by the
circumstances of the study.
 The signatures should represent the flow of the
consent process.
 When using LARs research is different than clinical
care
 Tell the IRB what you are doing!!

Questions?

